Please login to the form below

Not currently logged in
Email:
Password:

lumateperone

This page shows the latest lumateperone news and features for those working in and with pharma, biotech and healthcare.

Intra-Cellular soars on FDA approval of schizophrenia drug

Intra-Cellular soars on FDA approval of schizophrenia drug

Shares in the company rocketed over 178% yesterday as the news broke, after the FDA approved Caplyta (lumateperone) as a treatment for schizophrenia in adults.

Latest news

  • Intra-Cellular plans schizophrenia filing in 2018 Intra-Cellular plans schizophrenia filing in 2018

    Says lumateperone could provide additional benefits over existing treatments. US biotech company Intra-Cellular Therapies says it could file its lead drug lumateperone for schizophrenia as early as next year after ... Lumateperone is backed by two phase

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics